Two European markets. Two regulatory overhauls within eighteen months of each other. And almost nothing in common in terms of how cannabis is framed, accessed, prescribed or communicated.<\/p>\n
If you’re an anglophone cannabis company looking at Europe, this isn’t primarily a translation problem. It’s a regulatory linguistics problem. And the distinction matters more than most companies realise until they’ve already made a costly mistake.<\/p>\n
Same Product. Different Institutional Logic.<\/h2>\n
The most important thing to understand about Germany and Spain is that they’ve reached similar destinations \u2014 regulated medical cannabis access \u2014 through completely different institutional routes. And those routes leave a fingerprint on every piece of communication you produce.<\/p>\n
Germany built a pharmaceutical infrastructure.<\/strong> The MedCanG largely removed medical cannabis from the Narcotics Act and replaced the previous special narcotics prescription (the BtM-Rezept) with a standard prescription form. In principle, any licensed physician may now prescribe medical cannabis under the MedCanG framework, with dispensing handled through pharmacies across the country. The system is relatively decentralised and, until recently, compatible with telemedicine platforms \u2014 though proposed amendments to the MedCanG are moving to tighten those provisions.<\/p>\n Spain built a hospital system.<\/strong> Under RD 903\/2025, formulas must be prepared exclusively by authorised hospital pharmacy services, and prescriptions are reserved for specialist physicians in the relevant pathologies, requiring documented clinical justification. At present, dispensing is limited to hospital pharmacy services, though the decree explicitly leaves open the possibility of future participation by community pharmacies in exceptional cases. The framework leaves little room for the kind of telemedicine-driven prescribing ecosystem that emerged in Germany. The access point is the hospital, and the gatekeeper is a specialist.<\/p>\n This structural difference isn’t just administrative context. It defines what language is appropriate, what claims are viable, what tone is credible, and what a patient or professional needs to hear.<\/p>\n Here’s a concrete example of how this plays out.<\/p>\n In Germany, communications about medical cannabis increasingly circulate in a relatively accessible register. With the MedCanG removing the previous restriction to specific listed clinical indications, the prescription decision now depends primarily on the physician’s clinical judgement. This has contributed to a more conversational, patient-facing communication style in parts of the German cannabis market \u2014 one that addresses an informed audience navigating a relatively open prescribing environment.<\/p>\n In Spain, that tone would be a compliance problem and a credibility problem simultaneously. The model is, by design, highly medicalised and controlled: prescription is reserved to specialists, individualised clinical assessment is required, and access is generally contingent on documented failure of conventional treatments. Communications that suggest easy access, consumer choice or GP referral misrepresent the system entirely. The correct register is institutional, clinical and conservative \u2014 written for specialist physicians operating within a rigid public health framework, not for patients browsing their options.<\/p>\n Translate your German patient-facing content into Spanish, word for word, and you don’t just sound wrong. You sound non-compliant.<\/p>\n Beyond tone, the actual terminology differs in ways that don’t resolve neatly with a dictionary.<\/p>\n “F\u00f3rmula magistral tipificada”<\/strong> has no direct German equivalent because the underlying concept operates differently in each system. These standardised preparations must be formulated in accordance with the AEMPS monograph and prepared under the supervision of a hospital pharmacist according to the applicable Good Manufacturing Practices. This is a specific Spanish legal construct \u2014 a compounded preparation that has been standardised and registered nationally with the AEMPS. Translating it into German requires navigating a different pharmaceutical dispensing logic, not simply finding a matching term, because the institutional role that concept fills in the Spanish system doesn’t map directly onto German pharmaceutical practice.<\/p>\n “Preparados estandarizados de cannabis”<\/strong> in Spanish communicates AEMPS oversight, hospital pharmacy production and national registration. Under the MedCanG, medicinal cannabis is defined as plants, flowers and other parts of plants belonging to the genus cannabis originating from cultivation for medical purposes under state control. Same product category, different definitional logic, different regulatory anchors.<\/p>\n THC thresholds<\/strong> are stated differently in each jurisdiction. Under RD 903\/2025, preparations containing THC at or above 0.2% by weight are considered psychotropic and subject to additional control measures under the 1971 Convention on Psychotropic Substances. German communications around the same threshold reference different legislative frameworks \u2014 the MedCanG and its relationship to the now-reformed BtMG \u2014 and speak to different enforcement bodies. Using the Spanish framing in a German document, or vice versa, isn’t wrong in the way a typo is wrong. It signals that the author doesn’t actually understand the system they’re writing about.<\/p>\n Most cannabis companies entering Europe treat regulatory compliance as a legal checkbox: engage a local lawyer, review the claims, remove anything flagged. That approach is necessary but not sufficient.<\/p>\n What it doesn’t address is the underlying communication architecture \u2014 the institutional assumptions embedded in how you structure information, who you address it to, what you assume your reader already knows, and what level of clinical authority you invoke.<\/p>\n A German patient information document assumes the reader may have initiated the consultation themselves and is navigating a relatively open prescribing environment. A Spanish clinical communication assumes a specialist physician operating within a strictly controlled hospital protocol, prescribing for a patient who has exhausted conventional treatments.<\/p>\n These aren’t just different markets. They’re different relationships between the cannabis product and the institution that controls access to it. Getting that relationship wrong in writing \u2014 even if every individual claim is technically accurate \u2014 produces content that doesn’t land, doesn’t convert and doesn’t build trust.<\/p>\n If you’re preparing to communicate about medical cannabis in Germany and Spain, the starting question isn’t “how do we translate this?” It’s more fundamental than that.<\/p>\n Who is actually reading this? In Germany, it might be a patient who found out last week that their GP can now prescribe cannabis without a special form, or a specialist who’s been doing it for years. In Spain, in the current regulatory model, you’re almost certainly writing for a hospital specialist who operates inside a documented clinical protocol and has no interest in language that suggests the patient chose to be there.<\/p>\n That single answer changes everything: structure, register, the claims you make, the authority you invoke.<\/p>\n The institutional frame matters too. German physicians now work under a non-narcotic prescription framework \u2014 cannabis is no longer classified the way it previously was, and standard prescriptions apply. Spanish specialists operate within a public health system that is, by design, conservative and evidence-based. The language that reads as credible differs not just in degree but in kind.<\/p>\n And then there’s the legal scaffolding. Citing “compliance with MedCanG” in a Spanish document \u2014 or “compliance with RD 903\/2025” in a German one \u2014 isn’t just a localisation error. It tells the reader you didn’t read either law. In a regulated industry, that’s not a small thing.<\/p>\n Finally, advertising. Restrictions for prescription medicinal products remain tightly regulated in both markets: in Germany under the Heilmittelwerbegesetz (HWG); in Spain under the Ley de Garant\u00edas y Uso Racional de los Medicamentos y Productos Sanitarios. These frameworks aren’t interchangeable, and content built for one jurisdiction won’t automatically satisfy the other.<\/p>\n The wine industry figured this out decades ago. A producer entering the German market didn’t just translate the label. They understood that Qualit\u00e4tswein, Pr\u00e4dikatswein and the Pr\u00fcfungsnummer system were regulatory concepts that carried specific meaning for German buyers \u2014 and that getting them wrong was a signal of amateur execution, regardless of how good the wine was.<\/p>\n Cannabis is at the same inflection point, except the stakes are higher because the regulatory environment is younger, faster-moving and more consequential for patients.<\/p>\n What European cannabis expansion actually requires is not translation in the conventional sense. It’s the ability to read a regulatory framework and reconstruct the communication layer that belongs to it \u2014 tone, terminology, institutional address, claims architecture and all.<\/p>\n That’s what we mean by regulatory linguistics at Cannaspeaks<\/a>. And it’s the difference between content that opens doors in a new market and content that quietly closes them.<\/p>\n If you’re preparing communications for the German or Spanish medical cannabis markets, we’d be glad to talk. Contact us here.<\/a><\/em><\/p>\n Roc\u00edo del Amo<\/strong> is the founder of Cannaspeaks<\/a>, a boutique linguistic consultancy specialising exclusively in the cannabis sector. With 10+ years of experience in specialised translation \u2014 first in wine, now in cannabis \u2014 she works with international cannabis companies navigating European regulatory and linguistic complexity. About Roc\u00edo<\/a><\/p>","protected":false},"excerpt":{"rendered":" Germany and Spain now have medical cannabis laws \u2014 but the regulatory language is completely different. Here\u2019s what that means for your content.<\/p>","protected":false},"author":1,"featured_media":242210,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[23],"tags":[19,20,29,24,26,27,28,25],"class_list":["post-242214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-terminology-localization","tag-cannabis-localization","tag-cannabis-translation","tag-europe","tag-germany","tag-medcang","tag-rd-903-2025","tag-regulatory-compliance","tag-spain"],"yoast_head":"\nThe Language That Works in Berlin Won’t Work in Madrid<\/h2>\n
![\"Medical](\"https:\/\/cannaspeaks.com\/wp-content\/uploads\/2026\/05\/cannabis-regulatory-language-europe.jpg.png\")
<\/figure>\nTerminology: Where the Differences Get Granular<\/h2>\n
The Compliance Gap Is a Communication Gap<\/h2>\n
What This Means in Practice<\/h2>\n
The Case for Regulatory Linguistics<\/h2>\n
![\"Regulatory](\"https:\/\/cannaspeaks.com\/wp-content\/uploads\/2026\/05\/regulatory-linguistics-cannaspeaks.jpg.png\")
<\/figure>\n
\n
\nSources<\/h2>\n
\n
\n